FDA will consider Biogen's controversial drug as 1st new Alzheimer's treatment drug in 17 years
from Karma Impact
A controversial drug that treats the early stages of Alzheimer's disease might become the first medication for the disease in 17 years to win regulatory approval. Biogen Inc. said it plans to submit a regulatory filing for its aducanumab drug early next year — bringing it back into play seven months after the company appeared to abandon the drug by halting clinical trials.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063